Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/209428
Title: | Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy |
Author: | Bosch i Tubert, Fàtima Haurigot, Virginia Marcó, Sara Ribera, Albert García Martínez, Miguel Ruzo, Albert Villacampa, Pilar Ayuso, Eduard Añor Torres, Sònia Andaluz Martínez, Anna Pineda, Mercedes García-Fructuoso, Gemma Molas Laplana, Maria Maggioni, Luca Muñoz, Sergio Motas, Sandra Ruberte París, Jesús Mingozzi, Federico Pumarola i Batlle, Martí |
Keywords: | Lisosomes Teràpia genètica Líquid cefalorraquidi Lysosomes Gene therapy Cerebrospinal fluid |
Issue Date: | 1-Jul-2013 |
Publisher: | American Society for Clinical Investigation |
Abstract: | For most lysosomal storage diseases (LSDs) affecting the CNS, there is currently no cure. The BBB, which limits the bioavailability of drugs administered systemically, and the short half-life of lysosomal enzymes, hamper the development of effective therapies. Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomic recessive LSD caused by a deficiency in sulfamidase, a sulfatase involved in the stepwise degradation of glycosaminoglycan (GAG) heparan sulfate. Here, we demonstrate that intracerebrospinal fluid (intra-CSF) administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both CNS and somatic pathology in MPS IIIA mice. Following vector administration, enzymatic activity increased throughout the brain and in serum, leading to whole body correction of GAG accumulation and lysosomal pathology, normalization of behavioral deficits, and prolonged survival. To test this strategy in a larger animal, we treated beagle dogs using intracisternal or intracerebroventricular delivery. Administration of sulfamidase-encoding AAV9 resulted in transgenic expression throughout the CNS and liver and increased sulfamidase activity in CSF. High-titer serum antibodies against AAV9 only partially blocked CSF-mediated gene transfer to the brains of dogs. Consistently, anti-AAV antibody titers were lower in CSF than in serum collected from healthy and MPS IIIA-affected children. These results support the clinical translation of this approach for the treatment of MPS IIIA and other LSDs with CNS involvement. |
Note: | Reproducció del document publicat a: https://doi.org/10.1172/JCI66778 |
It is part of: | Journal of Clinical Investigation, 2013, vol. 123, num.8, p. 3254-3271 |
URI: | https://hdl.handle.net/2445/209428 |
Related resource: | https://doi.org/10.1172/JCI66778 |
ISSN: | 0021-9738 |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
254963.pdf | 12.45 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.